surmount-1 trial tirzepatide weight loss nondiabetic For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The SURMOUNT-1 Tirzepatide Trial — 22.5%
Description
Accountability through regular weigh-ins, whether self-directed or professionally supervised, helps maintain focus and allows early intervention when weight trends upward
The injection is delivered using a pre-filled, single-dose pen designed for easy at-home use
Focus on compound movements like squats, deadlifts, bench press, rows, and overhead press
J., Cartwright, B
